Why should C‑peptide be measured only when the concurrent plasma glucose is below 220 mg/dL, and not when glucose is higher?

Why C-Peptide Should Be Measured Only When Glucose Is Below 220 mg/dL

C-peptide measurement should be performed when concurrent plasma glucose is below 220 mg/dL because elevated glucose levels artificially suppress the C-peptide-to-glucose ratio and reduce the test's accuracy in assessing true beta cell function, leading to potential misclassification of diabetes type and inappropriate treatment decisions. 1

The Physiological Rationale

When plasma glucose exceeds 220 mg/dL, several factors compromise C-peptide interpretation:

• Glucose toxicity effects: Severely elevated glucose levels can temporarily suppress beta cell function, making residual insulin secretion appear lower than it actually is
• Ratio distortion: The C-peptide-to-glucose ratio becomes artificially low when the denominator (glucose) is excessively high, even if absolute C-peptide levels are adequate
• False classification risk: This can lead to misclassifying someone with Type 2 diabetes as having Type 1 diabetes, resulting in inappropriate insulin-only therapy when other agents might be beneficial

Evidence Supporting the 220 mg/dL Threshold

The 2023 American Diabetes Association guidelines specifically state this threshold for insurance coverage decisions regarding insulin pump therapy 1. This represents a Good Practice Point (GPP) recommendation, meaning it reflects expert consensus on optimal testing conditions.

Research demonstrates that C-peptide measurements are most reliable when concurrent glucose is ≥8 mmol/L (144 mg/dL) but not excessively elevated 2. When samples with glucose <8 mmol/L were excluded, the correlation between random and stimulated C-peptide improved from r=0.91 to r=0.96, and specificity for detecting clinically relevant thresholds increased to 100% 2.

Clinical Implications

For Diabetes Classification

C-peptide testing helps distinguish Type 1 from Type 2 diabetes in ambiguous cases 1, 3. The key thresholds are:

• <200 pmol/L (<0.2 nmol/L): Indicates severe insulin deficiency consistent with Type 1 diabetes
• >600 pmol/L (>0.6 nmol/L): Suggests preserved beta cell function consistent with Type 2 diabetes

These cutoffs lose validity when glucose is >220 mg/dL because the elevated glucose itself suppresses the C-peptide response.

For Treatment Decisions

Measuring C-peptide at inappropriately high glucose levels can lead to premature insulin intensification or inappropriate deprescribing of non-insulin agents 4. This is particularly problematic given the increasing use of SGLT2 inhibitors and GLP-1 receptor agonists, which require adequate residual insulin secretion to avoid diabetic ketoacidosis 4.

Common Pitfalls to Avoid

1. Don't measure C-peptide during acute hyperglycemic crises: Wait until glucose is controlled below 220 mg/dL
2. Don't rely on a single measurement: If initial testing occurs at high glucose, repeat when glucose is optimized
3. Consider timing: Fasting measurements are preferred for standardization, but random non-fasting C-peptide can be used if concurrent glucose is appropriate 2, 5

Practical Algorithm

When to measure C-peptide:

• Fasting glucose <220 mg/dL (preferred)
• OR random glucose between 144-220 mg/dL (acceptable)
• NOT when glucose >220 mg/dL

If glucose is >220 mg/dL:

• Optimize glycemic control first
• Retest when glucose is <220 mg/dL
• Consider using clinical presentation and autoantibodies for interim classification 1, 3

The 220 mg/dL threshold represents the upper limit where C-peptide measurement remains interpretable for clinical decision-making, balancing the need for adequate glucose stimulation against the confounding effects of severe hyperglycemia.